11 March 2019

PDMR Dealing

LONDON, March 11, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on March 8, 20…

Read more

7 March 2019

PDMR Dealing

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

Read more

5 March 2019

PDMR Dealing

LONDON, March 05, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on March 4, 20…

Read more

4 March 2019

Verona Pharma Reports Positive Interim Data with Ensifentrine Dry Powder Inhaler Formulation in First of Two-Part Phase 2 Clinical Trial in COPD

Single dose of ensifentrine DPI formulation produced statistically significant and clinically meaningful dose-dependent bronchodilator response and was well tolerated at all doses

Read more

28 February 2019

Verona Pharma to Present at Cowen and Company 39th Annual Health Care Conference

LONDON, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (NASDAQ: VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, today announces that the Co…

Read more

26 February 2019

Verona Pharma Reports Financial Results for Full Year Ended December 31, 2018 and Provides Clinical Development Update

LONDON, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces its audited results for…

Read more

20 February 2019

Verona Pharma to Announce Financial Results for Full Year ended December 31, 2018 and Provide Clinical Development Update

LONDON, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it will repo…

Read more

4 February 2019

Verona Pharma to Present at Upcoming Investor Conferences

LONDON, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (NASDAQ: VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, today announced that the Co…

Read more

14 January 2019

Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment

Results from this short clinical pharmacology trial inform and support further clinical development of ensifentrine as an add-on to dual and triple COPD therapy

Read more

9 January 2019

Verona Pharma Receives WHO Approval for “ensifentrine” as Recommended INN for RPL554

LONDON, Jan. 09, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that the Worl…

Read more

Targeting unmet needs

384m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients

Read more about COPD and CF in the unmet needs section of this website

Go

Basic & Clinical Pharmacology & Toxicology

Peer-reviewed publication on dual PDE3/4 inhibitors as novel treatments for COPD

The Lancet Respiratory Medicine

Peer-reviewed paper in the Lancet's highly-respected medication journal

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us